Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Brodalumab (Primary) ; Interleukin-17 inhibitors
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Bausch Health Companies; Ortho Dermatologics
- 31 Aug 2018 Biomarkers information updated
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 06 Apr 2018 Planned initiation date changed from 15 Mar 2018 to 15 Sep 2018.